Precision BioSciences
DTIL
About: Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Employees: 102
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
8% more funds holding
Funds holding: 48 [Q1] → 52 (+4) [Q2]
3.9% more ownership
Funds ownership: 36.13% [Q1] → 40.03% (+3.9%) [Q2]
3% more capital invested
Capital invested by funds: $18.1M [Q1] → $18.6M (+$579K) [Q2]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
Financial journalist opinion
Based on 3 articles about DTIL published over the past 30 days
